HealthQuill AbbeVie Inc.
The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.
Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

 HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat.

Read More
AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to acquire ImmunoGen, Inc., for $10.1 billion. Image Credit: AbbVie
Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.

Read More